Preparing for Microbicide Introduction, Rollout, and Sustained Access

  • Cynthia WoodsongEmail author
  • Elizabeth McGrory
  • Tim Farley
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 383)


Two topical vaginal microbicide candidates for HIV prevention are at an advanced stage of clinical testing, with efficacy results from three clinical trials expected within the next 2 years. Therefore, preparations for introducing and ensuring access to these products in the event that they are proven safe and effective now require increased attention. Microbicides are expected to fill an important global public health need for HIV prevention options for women. They have been developed almost exclusively with public and private funding through academic and nongovernmental institutions and minimal involvement of commercial pharmaceutical partners. Efficient and rapid introduction of a new public health technology requires a broad range of expertise and collaborations, some of which are new to the microbicide field as products are at last completing late-stage pivotal licensure studies. Strong leadership, political commitment, and considerable financial investments will be required to ensure successful distribution as well as uptake and continued access to this new product class. This paper highlights work conducted since 2000 by scientists, advocates, and public health officials to prepare for microbicide introduction, and discusses some of the needed actions to ensure that products will become readily accessible to the women who need them.


Female Condom Social Marketing Campaign National Regulatory Authority Microbicide Trial Microbicide Development 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors would like to thank Polly Harrison for her review and comments on an earlier draft of this paper.


  1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE et al (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996):1168–1174Google Scholar
  2. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T et al (2011) Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25(7):957–66 Epub 2011/02/19PubMedCrossRefGoogle Scholar
  3. Alliance for Microbicide Development (2007) Mapping the microbicide effort. Alliance for Microbicide Development, Silver SpringGoogle Scholar
  4. Alliance for Microbicide Development (2006) The microbicide development strategy. Alliance for Microbicide Development, Silver SpringGoogle Scholar
  5. Amico KR (2012) Adherence to pre-exposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS 7(6):542–8 Epub 2012/09/12PubMedCrossRefGoogle Scholar
  6. UNAIDS/AVAC (2011) Good participatory practice: guidelines for biomedical HIV prevention trials. UNAIDS, GenevaGoogle Scholar
  7. AVAC (2013) Research and Reality: AVAC Report 2013. Global Advocacy for HIV Prevention, NewYorkGoogle Scholar
  8. Becker JD, Cooper D, Harries J, Hoffman M, Orner P, Moodley J, McGrory E, Bracken H (2003) Paving the path: preparing for microbiocide introduction. Report of a qualitative study in South Africa. Engender Health, New YorkGoogle Scholar
  9. Bentley ME, Fullem AM, Tolley EE, Kelly CW, Jogelkar N, Srirak N et al (2004) Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am J Public Health 94(7):1159–64PubMedCentralPubMedCrossRefGoogle Scholar
  10. Brady E, McGrory E (2012) Shaping the Operations Research Agenda for Antiretroviral-Based Prevention products for Women: Gels and Rings. Population Council, New York Google Scholar
  11. Brady E, McGrory E (2007) Day of Dialogue. Insights and Evidence from Product Introduction: Lessons for Microbicides. Report of a meeting. Population Council, New YorkGoogle Scholar
  12. Brooks A, Smith TA, de Savigny D, Lengeler C (2012) Implementing new health interventions in developing countries: why do we lose a decade or more? BMC Public Health 12:683 (Epub 2012/08/23)Google Scholar
  13. Brown G, Raghavendran F, Walker S (2007) Planning for microbicide access in developing countries: lessons from the introduction of contraceptive technologies. International Partnership for Microbicides, Silver SpringGoogle Scholar
  14. Braunstein S, Van De Wijgert J (2005) Preference and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing. J Women Health 14(5):424–433CrossRefGoogle Scholar
  15. Coplan PM, Mitchnick M, Rosenberg ZF (2004) Regulatory challenges in microbicide development. Science 304(5679):1911–2 Epub 2004/06/26PubMedCrossRefGoogle Scholar
  16. Darroch JE, Frost JJ (1999) Women’s interest in vaginal microbicides. Fam Plan Perspec 31(1):16–23CrossRefGoogle Scholar
  17. Elias C, Coggins C (2001) Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: where have we been? where are we going? J Women Health Gen-B 10(2):163–73CrossRefGoogle Scholar
  18. EMA (2012) Reflection paper on the non-clinical and clinical development for oral and topical HIV pre-exposure prophylaxis (PrEP).
  19. Evangeli M, Engelbrecht SK, Swartz L, Turner K, Forsberg L, Soka N (2009) An evaluation of a brief motivational interviewing training course for HIV/AIDS counsellors in Western Cape Province. South Africa. AIDS Care 21(2):189–96 Epub 2009/02/21CrossRefGoogle Scholar
  20. FACTS (2014) FACTS001 study.
  21. FDA (2012) Draft guidance for industry—vaginal microbicides: development for the prevention of HIV infection. Food and Drug Administration, Center for Drug Evaluation and Research, RockvilleGoogle Scholar
  22. FDA (2012b) Guidance for Industry: Vaginal Microbicides Development for the Prevention of HIV Infection. Food and Drug Administration, RockvilleGoogle Scholar
  23. FHI360 (2014) Advocacy brief: gender considerations for microbicide introduction. Accessed Dec 2013
  24. Frost LJR MR (2009) Access: how do good health technologies get to poor people in poor countries? Harvard Center for Population and Development Studies, BostonGoogle Scholar
  25. Hankins CA, Dybul MR (2013) The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review. Curr Opin HIV AIDS 8(1):50–8 Epub 2012/12/04PubMedCrossRefGoogle Scholar
  26. Harrison P (2007) Origins, mandate, and activities of the “quick” clinical trials working group. In: Presentation to the Institute of Medicine committee on methodological challenges in HIV prevention trials. Washington DC, 6–7 Feb 2007Google Scholar
  27. Harrison PF (1999) A new model for collaboration: the Alliance for Microbicide Development. Int J Gyn Ob 67(Suppl 2):S39–53 Epub 2000/02/08CrossRefGoogle Scholar
  28. Herman L, Oudin A (2010) PDP access strategy discussion paper. In: PDP Access Workgroup.
  29. Hilber AM et al (2007) Vaginal practices, microbicides and HIV: what do we need to know? Sex Trans Infec 83(7):505–508CrossRefGoogle Scholar
  30. Hoffman S, Cooper D, Ramjee G, Higgins JA, Mantell JE (2008) Microbicide acceptability: insights for future directions from providers and policy makers. AIDS Ed Prev 20(2):188–202 Epub 2008/04/25CrossRefGoogle Scholar
  31. IPM (2007) Microbicide access forum draft meeting report. Nairobi, Kenya, International Partnership for Microbicides, Silver SpringGoogle Scholar
  32. IPM (2008) Microbicide access forum meeting report. Mexico City, International Partnership for Microbicides, Silver SpringGoogle Scholar
  33. Kim SC, Becker S, Dieffenbach C, Hanewall BS, Hankins C, Lo YR et al (2010) Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. J Int AIDS Society 13:24 (Epub 2010/07/14)Google Scholar
  34. Mandelbaum-Schmid J (2004) New generation of non-profit initiatives tackles world’s “neglected” diseases. B World Health Organ 82(5):395–6 Epub 2004/08/10Google Scholar
  35. Mantell JE, Needham SL, Smit JA, Hoffman S, Cebekhulu Q, Adams-Skinner J et al (2009) Gender norms in South Africa: implications for HIV and pregnancy prevention among African and Indian women students at a South African tertiary institution. Cult Health Sex 11(2):139–57 Epub 2009/02/28PubMedCentralPubMedCrossRefGoogle Scholar
  36. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C et al (2013) Pre-exposure Prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the voice study (mtn 003) (paper #26lb). In: 20th conference on retorviruses and opportunistic infections; 3-6 Mar 2013, Georgia World Conference Center, AtlantaGoogle Scholar
  37. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M et al (2010) PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a Phase 3, randomised, double-blind, parallel-group trial. Lancet 376(9749):1329–37PubMedCentralPubMedCrossRefGoogle Scholar
  38. McGrory EG, Gupta G (2002) Preparing for microbicides access. The Rockefeller Foundation Microbicide Initiative, NewYorkGoogle Scholar
  39. Montgomery CM, Gafos M, Lees S, Morar NS, Mweemba O, Ssali A et al (2010) Re-framing microbicide acceptability: findings from the MDP301 trial. Cult Health Sex 12(6):649–62PubMedCrossRefGoogle Scholar
  40. Morin SF, Maiorana A, Koester KA, Sheon NM, Richards TA (2003) Community consultation in HIV prevention research: a study of community advisory boards at 6 research sites. J Acq Immun Def Synd 33(4):513–20CrossRefGoogle Scholar
  41. Morrow KM, Fava JL, Rosen RK, Christensen AL, Vargas S, Barroso C (2007) Willingness to use microbicides varies by race/ethnicity, experience with prevention products, and partner type. Health Psychol 26(6):777–86 Epub 2007/11/21PubMedCentralPubMedCrossRefGoogle Scholar
  42. MTN (Microbicide Trials Network) (2014) A multi-center, randomized, double-blind, placebo-controlled Phase 3 safety and efectiveness trial of a vaginal matrix ring containing dapivirine for the prevention of hiv-1 infection in women (MTN-020). Microbicide trials network.
  43. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY et al (2007) SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PloS One 2(12):e1312PubMedCentralPubMedCrossRefGoogle Scholar
  44. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M et al (2010) Assessing the accuracy of adherence and sexual behaviour data in the MDP301 vaginal microbicides trial using a mixed methods and triangulation model. PloS One 5(7):e11632Google Scholar
  45. Ratzan SC (2007) Public-private partnerships for health. J Health Commun 12(4):315–6 Epub 2007/06/15PubMedCrossRefGoogle Scholar
  46. Severy L, Newcomer S (2005) Critical issues in contraception and STI acceptability research. J Soc Issues 61(1):45–65CrossRefGoogle Scholar
  47. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Fried-land B et al (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372(9654):1977–87 Epub 2008/12/09PubMedCrossRefGoogle Scholar
  48. Stone A, Harrision P (2010) Microbicides, the way forward. Alliance for Microbicide Development, Silver SpringGoogle Scholar
  49. Stone A (2009) Regulatory issues in microbicide development.
  50. Tedrow VA, Zelaya CE, Kennedy CE, Morin SF, Khumalo-Sakutukwa G, Sweat MD et al (2012) No “magic bullet”: exploring community mobilization strategies used in a multi-site community based randomized controlled trial: Project Accept (HPTN 043). AIDS Behav 16(5):1217–26 Epub 2011/08/09PubMedCentralPubMedCrossRefGoogle Scholar
  51. Terris-Prestholt F, Foss AM, Cox AP, Heise L, Meyer-Rath G, Delany-Moretlwe S et al (2014) Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. BMC Infect Dis 14:14 (Epub 2014/01/11)Google Scholar
  52. Tindana PO, Singh JA, Tracy CS, Upshur REG, Daar AS, Singer PA et al (2007) Grand challenges in global health: community engagement in research in developing countries. PLoS Med 4(9):e273PubMedCentralPubMedCrossRefGoogle Scholar
  53. Tolley EE, Eng E, Kohli R, Bentley ME, Mehendale S, Bunce A et al (2006) Examining the context of microbicide acceptability among married women and men in India. Cult Health Sex 8(4):351–69 Epub 2006/07/19PubMedCrossRefGoogle Scholar
  54. Tolley EF, B Gafos M, Amico R, Van Damme L, Woodsong C, MacQueen K, Mansoor L, McCormack S (in press) Drug delivery and development of Anti-HIV microbicides. In: das Neves J (ed) Socioeconomic and behavioral factors influencing choice, adherence and success of microbicide formulations. Pan Stanford Publishing, SingaporeGoogle Scholar
  55. UNAIDS/AVAC (2011) Good Participatory Practice: Guidelines for biomedical HIV prevention trials. UNAIDS, GenevaGoogle Scholar
  56. USAID (2013) USAID proposal for a shared vision and strategic plan for microbicide introduction. USAID, WashingtonGoogle Scholar
  57. Vallely A, Shagi C, Kasindi S, Desmond N, Lees S, Chiduo B et al (2007) The benefits of participatory methodologies to develop effective community dialogue in the context of a microbicide trial feasibility study in Mwanza, Tanzania. BMC Public Health 7:133PubMedCentralPubMedCrossRefGoogle Scholar
  58. Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Beck-er ML et al (2008) Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 359:463–72PubMedCrossRefGoogle Scholar
  59. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H et al (2002) Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360(9338):971–7PubMedCrossRefGoogle Scholar
  60. van der Straten A, Montgomery ET, Cheng H, Wegner L, Masenga G, von Mollendorf C et al (2012) high acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav 2012 (Epub 2012/05/31)Google Scholar
  61. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR (2012b) Un-raveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26(7):F13–9 Epub 2012/02/16PubMedCrossRefGoogle Scholar
  62. Verguet S, Walsh JA (2010) Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA. Sex Transm Infect 86(3):212–6PubMedCrossRefGoogle Scholar
  63. Vickerman P, Watts C, Delany S, Alary M, Rees H, Heise L (2006) The importance of context: model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sex Transm Dis 33(6):397–405PubMedCrossRefGoogle Scholar
  64. Walker SM, West S, Raghavendran V (2006) Framework for future microbicide access in developing countries. In: International AIDS conference; Mexico CityGoogle Scholar
  65. Watts C, Vickerman P (2001) The impact of microbicides on HIV and STD transmission: model projections. AIDS 15(S):s43–s4Google Scholar
  66. Whitehead SJ, McLean C, Chaikummao S, Braunstein S, Utaivoravit W, van de Wijgert JH et al (2011) Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai Thailand. PloS one 6(9):e14831 Epub 2011/09/15PubMedCentralPubMedCrossRefGoogle Scholar
  67. WHO (2012a) Scientific and technical requirements to formulate a female condom generic specific specification and prequalification scheme. WHO, Geneva. (
  68. WHO (2012b). WHO handbook for guideline development. Geneva, Switzerland: World Health Organization 2012.
  69. WHO (2013a) HIV preventives technology and market landscape. WHO, Geneva.
  70. WHO (2013b) Prequalification of medicines by WHO. Fact sheet No. 278, updated January 2013.
  71. WHO. WHO expert committee on specifications for pharmaceutical preparations. WHO, GenevaGoogle Scholar
  72. WHO/UNAIDS. (2010) Next steps with 1% tenofovir gel. Johannesburg, South Africa WHO/UNAIDS meeting: WHO/UNAIDS, 25-26 August 2010, WHO, GenevaGoogle Scholar
  73. Widdus R (2005) Public-private partnerships: an overview. T Roy Soc Trop Med H 99(Suppl 1):S1–8 Epub 2005/08/09CrossRefGoogle Scholar
  74. Wilson DP, Coplan PM (2008) Mathematical models and health economic aspects of microbicides. Curr Opin HIV AIDS 3(5):587–92PubMedCrossRefGoogle Scholar
  75. Woodsong C, Alleman P (2008) Sexual pleasure, gender power and microbicide acceptability in Zimbabwe and Malawi. AIDS Educ Prev 20(2):171–87 Epub 2008/04/25PubMedCrossRefGoogle Scholar
  76. Woodsong C, Alleman P, Musara P, Chandipwisa A, Chirenje M, Martinson F et al (2012) Preventive misconception as a motivation for participation and adherence in microbicide trials: evidence from female participants and male partners in Malawi and Zimbabwe. AIDS Behav 16(3):785–90 Epub 2011/08/25PubMedCentralPubMedCrossRefGoogle Scholar
  77. Woodsong C, Koo HP (2002) Holistic view of acceptability among a multi-ethnic population of adult and teen women and men. In: Paper presented at Microbicides 2002, Antwerp, 12–15 May 2002Google Scholar
  78. Woodsong C, MacQueen K, Amico R, Friedland B, Gafos M, Mansoor L, Tolley E, McCormack S (2013) Microbicide clinical trial adherence: insights for introduction. J Int AIDS Society 16(1):18505. doi: 10.7448/IAS.16.1.18505 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Cynthia Woodsong
    • 1
    Email author
  • Elizabeth McGrory
    • 2
  • Tim Farley
    • 2
  1. 1.International Partnership for MicrobicidesSilver SpringUSA
  2. 2.Sigma 3 Services Sarl, Scientific and Statistical SolutionsNyonSwitzerland

Personalised recommendations